From the volcanic slopes of Mayon in Albay, Filipino scientists have drawn a new name into the scientific record — Streptomyces mayonensis, a bacterium born of extreme earth and belonging to the family responsible for most of humanity's antibiotics. Identified by University of the Philippines researchers through years of careful genomic and biochemical work, this organism carries properties active against drug-resistant infections and certain cancer cells, arriving at a moment when the global pipeline for new antibiotics has slowed to a troubling trickle. The discovery does not promise a cure,
Inquirer.net
· Jun 25, 2026
· health
· 8 min de leitura
High
Apuração: Verificado
UP researchers identify antibiotic-potential bacteria from Mayon Volcano
◉
Health & Medicine
8464 artigos relacionados
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% correspondência
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% correspondência
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% correspondência
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% correspondência
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% correspondência
Cobertura Relacionada
The Guardian · Aug 26
ADHD and autism complaints triple as NHS waits stretch to years
Complaints about autism and ADHD services in England tripled in five years as NHS waits exceed a year for most patients,…
News-Medical · Aug 26 Sewage monitoring detects pertussis outbreaks 10 weeks earlier than clinical reportsWastewater surveillance in Osaka detected pertussis DNA 4-16 weeks before clinical case reports, offering a proactive ea…
The Hindu · Aug 26 India's H1N1 surge is seasonal, not a new strain, ICMR assuresIndia experiences seasonal H1N1 rise with 1,777 cases in Delhi and 4,212 in Karnataka; ICMR confirms it's the familiar p…
Medical Xpress · Aug 26 Stress gene hyperactivity linked to schizophrenia in University of Sydney studyUniversity of Sydney researchers discovered that a stress-regulating gene (FKBP5) remains abnormally active in schizophr…
Viés e Enquadramento
Não há dados de análise detalhada para esta lente. Tente executar as lentes novamente no painel de administração.
Impacto Geopolítico
🌎
Philippine researchers discover antibiotic-producing bacteria in volcanic soil, positioning the nation as a potential contributor to global pharmaceutical development amid antibiotic resistance crisis.
Escalation Risk
low
Confidence
HIGH
Philippines
Global (WHO member states)
Southeast Asia
Enhances Philippines' soft power and scientific credibility in global health governance; strengthens position in international pharmaceutical and biotechnology markets; potential leverage in future drug development partnerships and technology transfer negotiations with developed nations.
Similar to Brazil's biodiversity diplomacy using Amazon resources in pharmaceutical negotiations, or Madagascar's leverage of endemic species in drug discovery partnerships—biodiverse nations converting natural resources into scientific and economic influence.
Lente Econômica
📈
UP researchers discover new antibiotic-producing bacterial species from Mayon Volcano, potentially contributing to global efforts against drug-resistant infections and positioning Philippines as a biodiversity resource for pharmaceutical development.
Market Signal
bullish
Confidence
MED
Pharmaceutical and biotechnology
Healthcare and medical services
Research and development
Agriculture and natural resource management
Tourism (scientific/ecotourism)
Potential long-term benefit through development of new antibiotics to treat drug-resistant infections, reducing healthcare costs and improving treatment outcomes. However, commercialization timeline is uncertain and benefits are speculative.
Government may increase R&D funding for biodiversity exploration and pharmaceutical research. Potential need for intellectual property frameworks to protect discoveries and ensure equitable benefit-sharing. Possible incentives for biotech sector development and university-industry partnerships.